Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum Plasma Concentration (Cmax)
Cmax was obtained directly from the concentration-time data.
Blood samples were collected on Day 1 (pre-dose, then 1h30, 3h, 3h15, 3h30, 4h, 6h and 8h), Day 2, Day 3, Day 4 and Day 8 during ixabepilone administration and repeated for Cycle 2 (Days 22-25 and 29) during ixabepilone and rifampin co-administration.
United States: Food and Drug Administration
|The Cleveland Clinic Foundation||Cleveland, Ohio|